India’s first CNS Tumor Methylation Classifier can categorise brain tumors into subtypes, offering more accurate and personalised treatment planning for patients
MedGenome announced the launch of the country’s first CNS Tumor Methylation Classifier Test. This diagnostic test can differentiate and classify over 90 classes of brain and central nervous system (CNS) tumours into accurate subtypes, enabling doctors to make optimal and accurate treatment decisions. The test was unveiled in the presence of nearly 200 oncologists, neuro-onco surgeons and pathologists, researchers, and doctoral students at a precision oncology symposium in Mumbai, hosted by MedGenome jointly with Illumina, the global market leader in DNA sequencing and life sciences technologies.
VL Ramprasad, CEO, MedGenome, said, “No two cancers are truly the same, even in patients with the same diagnosis. A brain tumor in one person can behave very differently from an apparently similar tumour in another. Tools like whole-genome methylation profiling give us the resolution to see those differences clearly, so treatment can be planned for the specific individual. At MedGenome, our mission is to enable early diagnosis and targeted disease management through genetic and molecular-level insights. Science and innovation are at the core of our work. This first-of-its-kind, genomic test is a testament to our commitment to developing science-backed, affordable omics solutions for the world.”
